Targeting Tumor-Associated Carbonic Anhydrases in Photothermal Therapy

Area of Science:

• Oncology
• Biochemistry
• Biomedical Engineering

Background:

• Tumor-associated human carbonic anhydrases (hCAs), specifically hCA IX and hCA XII, are overexpressed in hypoxic tumor regions.
• These hCAs are critical for pH regulation, cancer cell survival, and invasiveness, making them attractive therapeutic targets.
• Photothermal therapy (PTT) uses near-infrared (NIR) light and light-absorbing agents to generate heat, inducing cancer cell apoptosis.

Purpose of the Study:

• To review recent advancements in developing hCA-targeted photothermal agents for cancer therapy.
• To explore the integration of hCA inhibition strategies with PTT for enhanced tumor treatment.
• To highlight the potential of combining hCA inhibition with PTT for precise and effective cancer therapies.

Main Methods:

• Review of recent scientific literature on hCA-targeted photothermal agents and combination therapies.
• Focus on tumor-associated isoforms hCA IX and hCA XII.
• Analysis of strategies for improving the efficacy and specificity of PTT through hCA targeting.

Main Results:

• hCA-targeted photothermal agents demonstrate potential for selective cancer cell ablation.
• Inhibition of hCAs can enhance both the efficacy and specificity of PTT.
• Combination therapy integrating hCA inhibition and PTT offers a promising approach for cancer treatment.

Conclusions:

• Combining hCA inhibition with PTT represents an innovative therapeutic strategy for cancer.
• Further research is needed to improve the biocompatibility, stability, and clinical translation of these agents.
• This approach holds promise for advancing more precise and effective cancer treatments.